Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	6.38T +61.3%
Revenue (ttm)	1.66T +12.9%
Net Income	217.04B +102.2%
EPS	17,099.95 +102.0%
Shares Out	12.69M
PE Ratio	29.42
Forward PE	29.14
Dividend	2,000.00 (0.40%)
Ex-Dividend Date	Mar 30, 2026

Volume	115,488
Open	511,000
Previous Close	515,000
Day's Range	500,000 - 519,000
52-Week Range	302,000 - 647,000
Beta	0.56
Analysts	Buy
Price Target	650,833.33 (+29.39%)
Earnings Date	Oct 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Analyst Summary

According to 12 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩650,833, which is an increase of 29.39% from the latest price.

Price Target

₩650,833

(29.39% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error